PD1/PD-L1免疫检查点抑制剂治疗非小细胞肺癌的研究进展

doi:10.13481/j.1671-587x.20190440

摘要/Abstract

摘要： 程序性死亡受体1（PD-1）/程序性死亡配体1（PD-L1）信号通路是诱导肿瘤免疫逃逸的主要机制，在肿瘤形成中起免疫检查点的作用。PD-1/PD-L1免疫检查点抑制剂通过阻断该通路而用于肿瘤的治疗。近年来，PD-1/PD-L1免疫检查点抑制剂在非小细胞肺癌（NSCLC）的治疗上取得了巨大的突破。大量国际性临床研究证实PD-1抗体和PD-L1抗体单药及联合化疗或血管生成抑制剂等药物治疗NSCLC的疗效明显优于传统化疗。Nivolumab、Pembrolizumab和Atezolizumab等免疫检查点抑制剂已获美国食品药品监督管理局（FDA）批准，成为NSCLC的二线治疗以及某些特定人群一线治疗的标准治疗策略。目前公认的与免疫治疗疗效确切相关的生物标志物主要有PD-L1表达水平、高度微卫星不稳定性（MSI-H）/MMR蛋白表达缺失（dMMR）和肿瘤突变负荷（TMB）。现将对免疫检查点抑制剂的作用机制、抗PD-1/PD-L1新药在NSCLC治疗中的临床研究进展及疗效预测生物标志物的选择进行综合评述。

关键词: 免疫治疗, 免疫检查点抑制剂, 程序性死亡受体1, 程序性死亡配体1, 癌,非小细胞肺

中图分类号:

R734.2

王钰聪, 徐英辉, 李宏伟, 王旭, 孙超, 郭晔, 邱实, 马克威. PD1/PD-L1免疫检查点抑制剂治疗非小细胞肺癌的研究进展[J]. 吉林大学学报(医学版), 2019, 45(04): 965-970.

参考文献

[1] ISHIDA Y, AGATA Y, SHIBAHARA K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11):3887-3895.
[2] HE J, HU Y, HU M, et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J]. Sci Rep, 2015, 5:13110.
[3] MEYERS D E, BRYAN P M, BANERJI S, et al. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer[J]. Curr Oncol, 2018, 25(4):324-334.
[4] CEERAZ S, NOWAK E C, NOELLE R J. B7 family checkpoint regulators in immune regulation and disease[J]. Trends Immunol, 2013, 34(11):556-563.
[5] FIFE B, BLUESTONE J. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J]. Immunol Rev, 2008, 224:166-182.
[6] MAMALIS A, GARCHA M, JAGDEO J. Targeting the PD-1 pathway:a promising future for the treatment of melanoma[J]. Arch Dermatol Res, 2014, 306(6):511-519.
[7] LIANG S C, LATCHMAN Y E, BUHLMANN J E, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses[J]. Eur J Immunol, 2003, 33(10):2706-2716.
[8] LI XL, SHAO CS, SHI YF, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy[J]. J Hematol Oncol, 2018, 11(1):31.
[9] THOMPSON R H, GILLETT M D, CHEVILLE J C, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma[J]. Cancer, 2005, 104(10):2084-2091.
[10] TAUBE J M, ANDERS R A, YOUNG G D, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J]. Sci Translk Med, 2012, 4(127):127ra37.
[11] DONG H, ZHU G, TAMADA K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12):1365-1369.
[12] HIRANO F, KANEKO K, TAMURA H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity[J]. Cancer Res, 2005, 65(3):1089-1096.
[13] DONG H, STROME S E, SALOMAO D R, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8):793-800.
[14] TOPALIAN S L, TAUBE J M, ANDERS R A, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16(5):275-287.
[15] CARBOGNIN L, PILOTTO S, MILELLA M, et al. Differential Activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1(PD-L1):sensitivity analysis of trials in melanoma, lung and genitourinary cancers[J]. PLoS One, 2015, 10(6):e0130142.
[16] MA W J, GILLIGAN B M, YUAN J D, et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy[J]. J Hematol Oncol, 2016, 9(1):47-67.
[17] RECK M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer[J]. Immunotherapy, 2018, 10(2):93-105.
[18] LI J, JIE H B, LEI Y, et al. PD-1/SHP-2 inhibit Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment[J]. Cancer Res, 2015, 75(3):508-518.
[19] SZNOL M, CHEN L. Antagonist antibodies to PD-1 and B7-H1(PD-L1) in the treatment of advanced human cancer:response[J]. Clin Cancer Res, 2013, 19(19):5542.
[20] JUNEJA V R, MCGUIRE K A, MANGUSO R T, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity[J]. J Exp Med, 2017, 214(4):895-904.
[21] TOPALIAN SL, HODI FS, BRAHMER JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-2454.
[22] GETTINGER S N, HORN L, GANDHI L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 33(18):2004-2012.
[23] GETTINGER S, HORN L, JACKMAN D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer:results from the CA209-003 study[J]. J Clin Oncol, 2018, 36(17):1675-1684.
[24] RIZVI N A, MAZIÈRES J, PLANCHARD D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial[J]. Lancet Oncol, 2015, 16(3):257-265.
[25] HORN L, SPIGEL D R, VOKES E E, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer:Two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35):3924-3933.
[26] FONT E F, GETTINGER S N, BURGIO M A, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057):3-year update and outcomes in patients with liver metastases[J]. Ann Oncol, 2018, 29(4):959-965.
[27] WU Y, LU S, CHENG Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC):results of the phase 3 CheckMate 078 study[C]. Chicago:AACR Annual Meeting, 2018.
[28] CARBONE D P, RECK M, PAZARES L, et al. First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer[J]. N Engl J Med, 2017, 39(25):2415-2426.
[29] HELLMANN M D, CIULEANU T E, PLUZANSKI A,et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104.
[30] PAI-SCHERF L, BLUMENTHAL G M, LI H S, et al. FDA approval summary:pembrolizumab for treatment of metastatic non-small cell lung cancer:first-line therapy and beyond[J]. Oncologist, 2017, 22(11):1392-1399.
[31] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550.
[32] HUI R, GARON E B, GOLDMAN J W, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer:a phase 1 trial[J]. Ann Oncol, 2017, 28(4):874-881.
[33] BORGHAEI H, LANGER C J, GADGEEL S, et al.24-Month overall survival from KEYNOTE-021 cohort G:pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small-cell lung cancer[J]. J Thorac Oncol, 2019.14(1):124-129.
[34] GANDHI L, RODRÍGUEZ-ABREUD,GADGEELS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092.
[35] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051.
[36] HERBST R S, SORIA J C, KOWANETZ M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528):563-567.
[37] FEHRENBACHER L, SPIRA A, BALLINGER M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846.
[38] RITTMEYER A, BARLESI F, WATERKAMP D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066):255-265.
[39] SOCINSKI M A, JOTTE R M, CAPPUZZO F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301.
[40] JOTTE R M, CAPPUZZO F,VYNNYCHENKO L, et al. IMpower131:Primary PFS and safety analysis of a randomized phase Ⅲ study of atezolizumab+carboplatin+paclitaxel or nab-paclitaxel vs carboplatin+nab-paclitacel as 1L therpay in advanced squamous NSCLC[J]. J Clin Oncol, 2018, 36(Suppl 18):LBA 9000.
[41] JIANG L Y, SU X Y, ZHANG T W, et al. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)[J]. Oncotarget, 2017, 8(16):26845-26857.
[42] HIRSCH F R, MCELHINNY A, STANFORTH D, et al. PD-L1 immunohistochemistry assays for lung cancer:results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2):208-222.
[43] MCLAUGHLIN J, HAN G, SCHALPER K A, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer[J]. JAMA Oncol, 2016, 2(1):46-54.
[44] HAUSE R J, PRITCHARD C C, SHENDURE J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nat Med, 2016, 22(11):1342-1350.
[45] RIZVI N A, HELLMANN M D, SNYDER A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124-128.